A review of 101 meta-analyses (50 observational and 51 clinical trials) shows that cannabis, cannabinoids and medications based on them can improve some medical conditions such as epilepsy, pain and inflammatory bowel disease, but harmful effects outweigh the benefitsespecially in certain population groups – adolescents and young people, people with a predisposition to mental disorders, pregnancy and drivers.
Specifically, an increase in the risk of psychosis in young people, adolescents and people with a predisposition to have a mental health problem; low weight in pregnant babies, and car accidents due to drowsiness.
This study, which contradicts popular belief that consuming cannabis has no consequences for health and that it represents the largest international study to date on cannabis, was published today by the British Medical Journal.
It has been led by Elena Dragioti, from Linkinging University; Marco Solmi, from the University of Ottawa, and Jae Il Shin, from Yonsei University. And he has had the participation of Eduard Vietahead of the Psychiatry and Psychology Service at the Hospital Clínic of Barcelona and the Bipolar and Depressive Disorders group at Idibaps, researcher at CIBERSAM and professor of Psychiatry at the University of Barcelona (UB), and Joaquim Raduàhead of the Image of Mood and Anxiety Related Disorders (IMARD) group at Idibaps, researcher at CIBERSAM and associate professor at the UB.
Vieta, in a meeting with Raduà with the press, confirmed that, according to this study, “no one under 25 years of age should consume cannabis.” He risk of developing psychosishe specified, occurs even in a single or first consumption opportunity. There could be a genetic factor behind it but he recalled that for now there is no way to know who is more or less at risk. It is estimated that there are 24 million people in the world with a disorder due to its use.